Bueno C, Almeida J, Lucio P, et al. Incidence and characteristics of CD4(+)/HLA DRhi dendritic cell malignancies. Haematologica 2004;89:58–69.

• PubMed
Bueno C, Almeida J, Lucio P, Incidence and characteristics of CD4(+)/HLA DRhi dendritic cell malignancies. Haematologica 2004;89:58–69.)| false
• Search Google Scholar
• Export Citation

Guru Murthy GS, Pemmaraju N, Atallah E. Epidemiology and survival of blastic plasmacytoid dendritic cell neoplasm. Leuk Res 2018;73:21–23.

• PubMed
Guru Murthy GS, Pemmaraju N, Atallah E. Epidemiology and survival of blastic plasmacytoid dendritic cell neoplasm. Leuk Res 2018;73:21–23.)| false
• Search Google Scholar
• Export Citation

Aoki T, Suzuki R, Kuwatsuka Y, et al. Long-term survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm. Blood 2015;125:3559–3562.

• PubMed
Aoki T, Suzuki R, Kuwatsuka Y, Long-term survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm. Blood 2015;125:3559–3562.)| false
• Search Google Scholar
• Export Citation

Sullivan JM, Rizzieri DA. Treatment of blastic plasmacytoid dendritic cell neoplasm. Hematology Am Soc Hematol Educ Program 2016;2016:16–23.

• PubMed
Sullivan JM, Rizzieri DA. Treatment of blastic plasmacytoid dendritic cell neoplasm. Hematology Am Soc Hematol Educ Program 2016;2016:16–23.)| false
• Search Google Scholar
• Export Citation

Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016;127:2391–2405.

• PubMed
Arber DA, Orazi A, Hasserjian R, The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016;127:2391–2405.)| false
• Search Google Scholar
• Export Citation

Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia 2022;36:1703–1719.

• PubMed
Khoury JD, Solary E, Abla O, The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia 2022;36:1703–1719.)| false
• Search Google Scholar
• Export Citation

Facchetti F, Petrella T, Pileri S. Blastic plasmacytoid dendritic cell neoplasm. In: Swerdlow SH, Campo E, Harris NL, et al., eds WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th ed. IARC; 2017:173–177.

• PubMed
Facchetti F, Petrella T, Pileri S. Blastic plasmacytoid dendritic cell neoplasm. In: Swerdlow SH, Campo E, Harris NL, , eds WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th ed. IARC; 2017:173–177.)| false
• Search Google Scholar
• Export Citation

Pagano L, Valentini CG, Pulsoni A, et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica 2013;98:239–246.

• PubMed
Pagano L, Valentini CG, Pulsoni A, Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica 2013;98:239–246.)| false
• Search Google Scholar
• Export Citation

Khanlari M, Yin CC, Takahashi K, et al. Bone marrow clonal hematopoiesis is highly prevalent in blastic plasmacytoid dendritic cell neoplasm and frequently sharing a clonal origin in elderly patients. Leukemia 2022;36:1343–1350.

• PubMed
Khanlari M, Yin CC, Takahashi K, Bone marrow clonal hematopoiesis is highly prevalent in blastic plasmacytoid dendritic cell neoplasm and frequently sharing a clonal origin in elderly patients. Leukemia 2022;36:1343–1350.)| false
• Search Google Scholar
• Export Citation

Dalle S, Beylot-Barry M, Bagot M, et al. Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice? Br J Dermatol 2010;162:74–79.

• PubMed
Dalle S, Beylot-Barry M, Bagot M, Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice? Br J Dermatol 2010;162:74–79.)| false
• Search Google Scholar
• Export Citation

Pemmaraju N, Lane AA, Sweet KL, et al. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med 2019;380:1628–1637.

• PubMed
Pemmaraju N, Lane AA, Sweet KL, Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med 2019;380:1628–1637.)| false
• Search Google Scholar
• Export Citation

Martín-Martín L, Almeida J, Pomares H, et al. Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy. Oncotarget 2016;7:10174–10181.

• PubMed
Martín-Martín L, Almeida J, Pomares H, Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy. Oncotarget 2016;7:10174–10181.)| false
• Search Google Scholar
• Export Citation

Feuillard J, Jacob MC, Valensi F, et al. Clinical and biologic features of CD4(+)CD56(+) malignancies. Blood 2002;99:1556–1563.

• PubMed
Feuillard J, Jacob MC, Valensi F, Clinical and biologic features of CD4(+)CD56(+) malignancies. Blood 2002;99:1556–1563.)| false
• Search Google Scholar
• Export Citation

Tsagarakis NJ, Kentrou NA, Papadimitriou KA, et al. Acute lymphoplasmacytoid dendritic cell (DC2) leukemia: results from the Hellenic Dendritic Cell Leukemia Study Group. Leuk Res 2010;34:438–446.

• PubMed
Tsagarakis NJ, Kentrou NA, Papadimitriou KA, Acute lymphoplasmacytoid dendritic cell (DC2) leukemia: results from the Hellenic Dendritic Cell Leukemia Study Group. Leuk Res 2010;34:438–446.)| false
• Search Google Scholar
• Export Citation

Sukswai N, Aung PP, Yin CC, et al. Dual expression of TCF4 and CD123 is highly sensitive and specific for blastic plasmacytoid dendritic cell neoplasm. Am J Surg Pathol 2019;43:1429–1437.

• PubMed
Sukswai N, Aung PP, Yin CC, Dual expression of TCF4 and CD123 is highly sensitive and specific for blastic plasmacytoid dendritic cell neoplasm. Am J Surg Pathol 2019;43:1429–1437.)| false
• Search Google Scholar
• Export Citation

Ceribelli M, Hou ZE, Kelly PN, et al. A druggable TCF4- and BRD4- dependent transcriptional network sustains malignancy in blastic plasmacytoid dendritic cell neoplasm. Cancer Cell 2016;30:764–778.

• PubMed
Ceribelli M, Hou ZE, Kelly PN, A druggable TCF4- and BRD4- dependent transcriptional network sustains malignancy in blastic plasmacytoid dendritic cell neoplasm. Cancer Cell 2016;30:764–778.)| false
• Search Google Scholar
• Export Citation

Wilson NR, Bover L, Konopleva M, et al. CD303 (BDCA-2) - a potential novel target for therapy in hematologic malignancies. Leuk Lymphoma 2022;63:19–30.

• PubMed
Wilson NR, Bover L, Konopleva M, CD303 (BDCA-2) - a potential novel target for therapy in hematologic malignancies. Leuk Lymphoma 2022;63:19–30.)| false
• Search Google Scholar
• Export Citation

Menezes J, Acquadro F, Wiseman M, et al. Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm. Leukemia 2014;28:823–829.

• PubMed
Menezes J, Acquadro F, Wiseman M, Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm. Leukemia 2014;28:823–829.)| false
• Search Google Scholar
• Export Citation

Batta K, Bossenbroek HM, Pemmaraju N, et al. Divergent clonal evolution of blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia from a shared TET2-mutated origin. Leukemia 2021;35:3299–3303.

• PubMed
Batta K, Bossenbroek HM, Pemmaraju N, Divergent clonal evolution of blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia from a shared TET2-mutated origin. Leukemia 2021;35:3299–3303.)| false
• Search Google Scholar
• Export Citation

Reimer P, Rüdiger T, Kraemer D, et al. What is CD4+CD56+ malignancy and how should it be treated? Bone Marrow Transplant 2003;32:637–646.

• PubMed
Reimer P, Rüdiger T, Kraemer D, What is CD4+CD56+ malignancy and how should it be treated? Bone Marrow Transplant 2003;32:637–646.)| false
• Search Google Scholar
• Export Citation

Frankel AE, Woo JH, Ahn C, et al. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood 2014;124:385–392.

• PubMed
Frankel AE, Woo JH, Ahn C, Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood 2014;124:385–392.)| false
• Search Google Scholar
• Export Citation

Pemmaraju N, Sweet KL, Stein AS, et al. Long-term benefits of tagraxofusp for patients with blastic plasmacytoid dendritic cell neoplasm. J Clin Oncol 2022;40:3032–3036.

• PubMed
Pemmaraju N, Sweet KL, Stein AS, Long-term benefits of tagraxofusp for patients with blastic plasmacytoid dendritic cell neoplasm. J Clin Oncol 2022;40:3032–3036.)| false
• Search Google Scholar
• Export Citation

Deotare U, Yee KW, Le LW, et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: 10-color flow cytometry diagnosis and HyperCVAD therapy. Am J Hematol 2016;91:283–286.

• PubMed
Deotare U, Yee KW, Le LW, Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: 10-color flow cytometry diagnosis and HyperCVAD therapy. Am J Hematol 2016;91:283–286.)| false
• Search Google Scholar
• Export Citation

Pemmaraju N, Wilson NR, Garcia-Manero G, et al. Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD. Blood Adv 2022;6:3027–3035.

• PubMed
Pemmaraju N, Wilson NR, Garcia-Manero G, Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD. Blood Adv 2022;6:3027–3035.)| false
• Search Google Scholar
• Export Citation

DiNardo CD, Rausch CR, Benton C, et al. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol 2018;93:401–407.

• PubMed
DiNardo CD, Rausch CR, Benton C, Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol 2018;93:401–407.)| false
• Search Google Scholar
• Export Citation

Prescribing information for venetoclax tablets, for oral use. 2022. Accessed March 24, 2023. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208573s027lbl.pdf

• PubMed
Prescribing information for venetoclax tablets, for oral use. 2022. Accessed March 24, 2023. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208573s027lbl.pdf)| false
• Search Google Scholar
• Export Citation

Montero J, Stephansky J, Cai T, et al. Blastic blasmacytoid dendritic cell neoplasm is dependent on BCL2 and sensitive to venetoclax. Cancer Discov 2017;7:156–164.

• PubMed
Montero J, Stephansky J, Cai T, Blastic blasmacytoid dendritic cell neoplasm is dependent on BCL2 and sensitive to venetoclax. Cancer Discov 2017;7:156–164.)| false
• Search Google Scholar
• Export Citation

Roos-Weil D, Dietrich S, Boumendil A, et al. Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood 2013;121:440–446.

• PubMed
Roos-Weil D, Dietrich S, Boumendil A, Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood 2013;121:440–446.)| false
• Search Google Scholar
• Export Citation

Kharfan-Dabaja MA, Al Malki MM, Deotare U, et al. Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study. Br J Haematol 2017;179:781–789.

• PubMed
Kharfan-Dabaja MA, Al Malki MM, Deotare U, Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study. Br J Haematol 2017;179:781–789.)| false
• Search Google Scholar
• Export Citation

Bruch PM, Dietrich S, Finel H, et al. Retrospective analysis of hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: conditioning intensity matters. Leukemia 2023;37:465–472.

• PubMed
Bruch PM, Dietrich S, Finel H, Retrospective analysis of hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: conditioning intensity matters. Leukemia 2023;37:465–472.)| false
• Search Google Scholar
• Export Citation

Pemmaraju N, Kantarjian H, Sweet K, et al. North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need. Blood 2023;141:567–578.

• PubMed
Pemmaraju N, Kantarjian H, Sweet K, North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need. Blood 2023;141:567–578.)| false
• Search Google Scholar
• Export Citation